{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:51:49Z","timestamp":1790736709757,"version":"4.1.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"FWO, Belgium","doi-asserted-by":"publisher","award":["1133120N"],"award-info":[{"award-number":["1133120N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004385","name":"Ghent University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011851","name":"Kom Op Tegen Kanker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"Stand up to Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001698","name":"Israel Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001698","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ygyno.2020.11.018","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T18:36:56Z","timestamp":1606502216000},"page":"633-642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Candidate RNA biomarkers in biofluids for early diagnosis of ovarian cancer: A systematic review"],"prefix":"10.1016","volume":"160","author":[{"given":"Eva","family":"Hulstaert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelien","family":"Morlion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren","family":"Levanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Vandesompele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Mestdagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2020.11.018_bb0005","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"issue":"10022","key":"10.1016\/j.ygyno.2020.11.018_bb0010","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","article-title":"Ovarian cancer screening and mortality in the UK collaborative trial of ovarian Cancer screening (UKCTOCS): a randomised controlled trial","volume":"387","author":"Jacobs","year":"2016","journal-title":"Lancet."},{"issue":"22","key":"10.1016\/j.ygyno.2020.11.018_bb0015","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian Cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) Cancer screening randomized controlled trial","volume":"305","author":"Buys","year":"2011","journal-title":"JAMA."},{"issue":"6","key":"10.1016\/j.ygyno.2020.11.018_bb0020","doi-asserted-by":"crossref","first-page":"850","DOI":"10.4161\/rna.20378","article-title":"Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases","volume":"9","author":"Weiland","year":"2012","journal-title":"RNA Biol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.11.018_bb0025","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-016-0536-0","article-title":"Clinical relevance of circulating cell-free microRNAs in ovarian cancer","volume":"15","author":"Nakamura","year":"2016","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ygyno.2020.11.018_bb0030","article-title":"Charting extracellular transcriptomes in The Human Biofluid RNA Atlas","author":"Hulstaert","year":"2019","journal-title":"bioRxiv"},{"issue":"4","key":"10.1016\/j.ygyno.2020.11.018_bb0035","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.cell.2018.12.021","article-title":"The Landscape of Circular RNA in Cancer","volume":"176","author":"Vo","year":"2019","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.ygyno.2020.11.018_bb0040","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nrg2934","article-title":"RNA sequencing: advances, challenges and opportunities","volume":"12","author":"Ozsolak","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ygyno.2020.11.018_bb0045","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ygyno.2020.11.018_bb0050","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"issue":"8","key":"10.1016\/j.ygyno.2020.11.018_bb0055","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2020.11.018_bb0060","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s13205-020-2124-7","article-title":"Evaluation of miR-22 and miR-21 as diagnostic biomarkers in patients with epithelial ovarian cancer","volume":"10","author":"Paliwal","year":"2020","journal-title":"3 Biotech"},{"issue":"8","key":"10.1016\/j.ygyno.2020.11.018_bb0065","first-page":"1675","article-title":"Integrated extracellular microRNA profiling for ovarian cancer screening","volume":"45","author":"Yokoi","year":"2019","journal-title":"J. Obstet. Gynaecol. Res."},{"issue":"6","key":"10.1016\/j.ygyno.2020.11.018_bb0070","first-page":"5601","article-title":"MicroRNA profiling of plasma exosomes from patients with ovarian cancer using high-throughput sequencing","volume":"17","author":"Zhang","year":"2019","journal-title":"Oncol. Lett."},{"issue":"9","key":"10.1016\/j.ygyno.2020.11.018_bb0075","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.7150\/jca.30231","article-title":"Serum exosomal miRNA-145 and miRNA-200c as promising biomarkers for preoperative diagnosis of ovarian carcinomas","volume":"10","author":"Kim","year":"2019","journal-title":"J. Cancer"},{"issue":"11","key":"10.1016\/j.ygyno.2020.11.018_bb0080","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1002\/1878-0261.12371","article-title":"Exosomal microRNAs as tumor markers in epithelial ovarian cancer","volume":"12","author":"Pan","year":"2018","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.11.018_bb0085","first-page":"33","article-title":"Serum MicroRNA-21 negatively relates to expression of programmed cell Death-4 in patients with epithelial ovarian cancer","volume":"19","author":"Mahmoud","year":"2018","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"6","key":"10.1016\/j.ygyno.2020.11.018_bb0090","doi-asserted-by":"crossref","first-page":"999","DOI":"10.4149\/neo_2016_620","article-title":"Diagnostic accuracy of peripheral blood Kisspeptin mRNA and plasma CA125 protein for detection of epithelial ovarian cancer in patients who have ever been pregnant","volume":"63","author":"Chen","year":"2016","journal-title":"Neoplasma."},{"issue":"4","key":"10.1016\/j.ygyno.2020.11.018_bb0095","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/bjc.2013.795","article-title":"Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes","volume":"110","author":"Shapira","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"2 Pt B","key":"10.1016\/j.ygyno.2020.11.018_bb0100","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.canlet.2014.10.010","article-title":"A novel serum microRNA panel to discriminate benign from malignant ovarian disease","volume":"356","author":"Langhe","year":"2015","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.ygyno.2020.11.018_bb0105","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1158\/1078-0432.CCR-12-2726","article-title":"Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer","volume":"19","author":"Suryawanshi","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2020.11.018_bb0110","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.7314\/APJCP.2013.14.2.1057","article-title":"Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer","volume":"14","author":"Xu","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.ygyno.2020.11.018_bb0115","doi-asserted-by":"crossref","first-page":"9715","DOI":"10.2147\/OTT.S211413","article-title":"Utility of plasma circBNC2 as a diagnostic biomarker in epithelial ovarian Cancer","volume":"12","author":"Hu","year":"2019","journal-title":"Onco. Targets Ther."},{"issue":"11","key":"10.1016\/j.ygyno.2020.11.018_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225249","article-title":"Diagnostic plasma miRNA-profiles for ovarian cancer in patients with pelvic mass","volume":"14","author":"Oliveira","year":"2019","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.ygyno.2020.11.018_bb0125","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/iub.2153","article-title":"Role of a novel circulatory RNA-based biomarker panel expression in ovarian cancer","volume":"71","author":"El-Shal","year":"2019","journal-title":"IUBMB Life"},{"issue":"4","key":"10.1016\/j.ygyno.2020.11.018_bb0130","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.amjms.2019.07.005","article-title":"The value of plasma-based MicroRNAs as diagnostic biomarkers for ovarian Cancer","volume":"358","author":"Wang","year":"2019","journal-title":"Am J Med Sci"},{"issue":"7","key":"10.1016\/j.ygyno.2020.11.018_bb0135","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1111\/cas.14034","article-title":"circMAN1A2 could serve as a novel serum biomarker for malignant tumors","volume":"110","author":"Fan","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ygyno.2020.11.018_bb0140","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jbiotec.2019.04.003","article-title":"Circulating epithelial-mesenchymal transition-associated miRNAs are promising biomarkers in ovarian cancer","volume":"297","author":"M\u00e1rton","year":"2019","journal-title":"J. Biotechnol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.11.018_bb0145","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2174\/22115374OTY4aMzknTcVY","article-title":"The promising signatures of circulating microRNA-145 in epithelial ovarian cancer patients","volume":"9","author":"Zuberi","year":"2020","journal-title":"Microrna."},{"issue":"1","key":"10.1016\/j.ygyno.2020.11.018_bb0150","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13048-018-0477-x","article-title":"Upregulated expression of serum exosomal miR-375 and miR-1307 enhance the diagnostic power of CA125 for ovarian cancer","volume":"12","author":"Su","year":"2019","journal-title":"J. Ovarian Res."},{"issue":"1","key":"10.1016\/j.ygyno.2020.11.018_bb0155","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13048-018-0458-0","article-title":"Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types","volume":"11","author":"Kobayashi","year":"2018","journal-title":"J. Ovarian Res."},{"issue":"4","key":"10.1016\/j.ygyno.2020.11.018_bb0160","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1177\/1933719118776808","article-title":"Ascites-derived extracellular microRNAs as potential biomarkers for ovarian Cancer","volume":"26","author":"Z\u00e1vesk\u00fd","year":"2019","journal-title":"Reprod. Sci."},{"issue":"4","key":"10.1016\/j.ygyno.2020.11.018_bb0165","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s12253-018-0392-x","article-title":"Diagnostic model of serum miR-193a-5p, HE4 and CA125 improves the diagnostic efficacy of epithelium ovarian Cancer","volume":"24","author":"Ren","year":"2018","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.ygyno.2020.11.018_bb0170","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.canlet.2016.12.017","article-title":"Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: a validation across two independent cohorts","volume":"388","author":"Todeschini","year":"2017","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.ygyno.2020.11.018_bb0175","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/IGC.0000000000000846","article-title":"A pilot study of circulating MicroRNA-125b as a diagnostic and prognostic biomarker for epithelial ovarian Cancer","volume":"27","author":"Zhu","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2020.11.018_bb0180","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/bjc.2015.340","article-title":"Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients","volume":"113","author":"Meng","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2020.11.018_bb0185","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.3892\/or.2015.3937","article-title":"Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma","volume":"33","author":"Zhou","year":"2015","journal-title":"Oncol. Rep."},{"issue":"22","key":"10.1016\/j.ygyno.2020.11.018_bb0190","doi-asserted-by":"crossref","first-page":"19328","DOI":"10.18632\/oncotarget.2896","article-title":"Detection of high mobility group A2 specific mRNA in the plasma of patients affected by epithelial ovarian cancer","volume":"6","author":"Galdiero","year":"2015","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.ygyno.2020.11.018_bb0195","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1007\/s13277-015-3191-y","article-title":"Serum microRNA-145 as a novel biomarker in human ovarian cancer","volume":"36","author":"Liang","year":"2015","journal-title":"Tumour Biol."},{"issue":"6","key":"10.1016\/j.ygyno.2020.11.018_bb0200","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1007\/s13277-015-3138-3","article-title":"MicroRNA-200c and microRNA-141 as potential diagnostic and prognostic biomarkers for ovarian cancer","volume":"36","author":"Gao","year":"2015","journal-title":"Tumour Biol."},{"issue":"4","key":"10.1016\/j.ygyno.2020.11.018_bb0205","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.7314\/APJCP.2014.15.4.1739","article-title":"Differential microRNA expression by Solexa sequencing in the sera of ovarian cancer patients","volume":"15","author":"Ji","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"11","key":"10.1016\/j.ygyno.2020.11.018_bb0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077853","article-title":"Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer","volume":"8","author":"Zheng","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ygyno.2020.11.018_bb0215","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1177\/0300060513487652","article-title":"Serum microRNA-92 expression in patients with ovarian epithelial carcinoma","volume":"41","author":"Guo","year":"2013","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.ygyno.2020.11.018_bb0220","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1186\/1471-2407-12-627","article-title":"Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer","volume":"12","author":"Kan","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2020.11.018_bb0225","doi-asserted-by":"crossref","first-page":"e3233","DOI":"10.1002\/jgm.3233","article-title":"Serum lncRNA LOXL1-AS1 is a diagnostic and prognostic marker for epithelial ovarian cancer","author":"Liu","year":"2020","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ygyno.2020.11.018_bb0230","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.28932","article-title":"Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer","volume":"6","author":"Elias","year":"2017","journal-title":"Elife."},{"issue":"1","key":"10.1016\/j.ygyno.2020.11.018_bb0235","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1186\/s12885-018-4974-5","article-title":"Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells","volume":"18","author":"Yoshimura","year":"2018","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2020.11.018_bb0240","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1373\/jalm.2017.025809","article-title":"Study design considerations for Cancer biomarker discoveries","volume":"3","author":"Zheng","year":"2018","journal-title":"J. Appl. Lab. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2020.11.018_bb0245","first-page":"256","article-title":"Cancer biomarker discovery and validation","volume":"4","author":"Goossens","year":"2015","journal-title":"Transl. Cancer Res."},{"issue":"3","key":"10.1016\/j.ygyno.2020.11.018_bb0250","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ygyno.2014.03.575","article-title":"The clinical and diagnostic role of microRNAs in ovarian carcinoma","volume":"133","author":"Davidson","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.11.018_bb0255","doi-asserted-by":"crossref","first-page":"728","DOI":"10.2353\/ajpath.2007.070070","article-title":"MicroRNAs in tumorigenesis","volume":"171","author":"Zhang","year":"2007","journal-title":"Am. J. Pathol."},{"issue":"5","key":"10.1016\/j.ygyno.2020.11.018_bb0260","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell."},{"issue":"6","key":"10.1016\/j.ygyno.2020.11.018_bb0265","first-page":"2130","article-title":"FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner","volume":"52","author":"Wang","year":"2018","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2020.11.018_bb0270","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3892\/ol.2014.2723","article-title":"MiR-30a upregulates BCL2A1, IER3 and cyclin D2 expression by targeting FOXL2","volume":"9","author":"Wang","year":"2015","journal-title":"Oncol. Lett."},{"issue":"5","key":"10.1016\/j.ygyno.2020.11.018_bb0275","first-page":"6697","article-title":"miR-221 regulates proliferation and apoptosis of ovarian cancer cells by targeting BMF","volume":"16","author":"Xie","year":"2018","journal-title":"Oncol. Lett."},{"issue":"12","key":"10.1016\/j.ygyno.2020.11.018_bb0280","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/nm.2512","article-title":"miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response","volume":"17","author":"Mateescu","year":"2011","journal-title":"Nat. Med."},{"issue":"13","key":"10.1016\/j.ygyno.2020.11.018_bb0285","first-page":"4080","article-title":"MiR-200a promotes cell invasion and migration of ovarian carcinoma by targeting PTEN","volume":"22","author":"Suo","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.ygyno.2020.11.018_bb0290","doi-asserted-by":"crossref","first-page":"3404059","DOI":"10.1155\/2020\/3404059","article-title":"miR-200b\/200a\/429 cluster stimulates ovarian Cancer development by targeting ING5","volume":"2020","author":"Guan","year":"2020","journal-title":"J. Oncol."},{"key":"10.1016\/j.ygyno.2020.11.018_bb0295","doi-asserted-by":"crossref","first-page":"8329","DOI":"10.2147\/OTT.S220339","article-title":"MiR-200a-3p promoted the malignant behaviors of ovarian cancer cells through regulating PCDH9","volume":"12","author":"Shi","year":"2019","journal-title":"Onco. Targets Ther."},{"issue":"8","key":"10.1016\/j.ygyno.2020.11.018_bb0300","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s12032-014-0134-1","article-title":"miR-200c modulates ovarian cancer cell metastasis potential by targeting zinc finger E-box-binding homeobox 2 (ZEB2) expression","volume":"31","author":"Lu","year":"2014","journal-title":"Med. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2020.11.018_bb0305","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1158\/0008-5472.CAN-18-3668","article-title":"Inhibition of miR-328-3p impairs Cancer stem cell function and prevents metastasis in ovarian Cancer","volume":"79","author":"Srivastava","year":"2019","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.ygyno.2020.11.018_bb0310","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/cbin.11182","article-title":"miR-145 inhibits glutamine metabolism through c-myc\/GLS1 pathways in ovarian cancer cells","volume":"43","author":"Li","year":"2019","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.ygyno.2020.11.018_bb0315","doi-asserted-by":"crossref","first-page":"100828","DOI":"10.1016\/j.mam.2019.10.005","article-title":"Targets, pitfalls and reference materials for liquid biopsy tests in cancer diagnostics","volume":"72","author":"Geeurickx","year":"2020","journal-title":"Mol. Asp. Med."},{"issue":"5","key":"10.1016\/j.ygyno.2020.11.018_bb0320","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/bioinformatics\/btg484","article-title":"Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments","volume":"20","author":"Baggerly","year":"2004","journal-title":"Bioinformatics."},{"issue":"5","key":"10.1016\/j.ygyno.2020.11.018_bb0325","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1074\/mcp.RA119.001362","article-title":"Microvesicle proteomic profiling of uterine liquid biopsy for ovarian Cancer early detection","volume":"18","author":"Barnabas","year":"2019","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.ygyno.2020.11.018_bb0330","author":"GRAIL, Inc."},{"key":"10.1016\/j.ygyno.2020.11.018_bb0335","doi-asserted-by":"crossref","DOI":"10.1093\/database\/bau080","article-title":"miRBase Tracker: keeping track of microRNA annotation changes","volume":"2014","author":"Van Peer","year":"2014","journal-title":"Database"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820341299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820341299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:56:38Z","timestamp":1758772598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820341299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0090825820341299"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.11.018","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Candidate RNA biomarkers in biofluids for early diagnosis of ovarian cancer: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}